| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17127 R71769 |
Delteil - Beta-blockers, 2024 | Preterm birth (<37 GW) | at least 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: Only chronic indication (hypertension or cardiac) | 1.34 [0.99;1.82] | 42/453 6,845/141,888 | 6,887 | 453 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17156 R71953 |
Vaclavik - Beta-blockers, 2024 | Preterm delivery | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 2.04 [1.87;2.22] | -/602 -/71,860 | - | 602 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17151 R71927 |
Al Khalaf - Beta-blockers (Controls unexposed, disease free), 2022 | Preterm birth (less than 37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
3.00 [2.59;3.47] C excluded (control group) |
199/1,952 63,460/1,739,944 | 63,659 | 1,952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17148 R71904 |
Al Khalaf - Beta-blockers (Controls unexposed, sick), 2022 | Preterm birth (less than 37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 1.20 [1.01;1.41] C | 199/1,952 677/7,809 | 876 | 1,952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13995 R54972 |
Baard - Beta-blockers, 2020 | Preterm birth < 37 weeks | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 1.11 [0.50;2.44] C | 11/43 32/135 | 43 | 43 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13509 R52190 |
Fitton - Beta-blockers (Controls unexposed, disease free), 2020 | Preterm birth (birth on or before 36 weeks gestation). | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
2.36 [1.83;3.05] excluded (control group) |
128/985 12,622/250,693 | 12,750 | 985 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14420 R57246 |
Fitton - Beta-blockers (Controls unexposed, sick), 2020 | Preterm birth (birth on or before 36 weeks gestation). | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.47 [1.20;1.79] C | 128/985 736/7,971 | 864 | 985 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13853 R54277 |
Kayser - Metoprolol/bisoprolol, 2020 | Preterm birth (delivery before 37 completed gestational weeks) | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 2.20 [1.30;3.80] | 45/294 56/588 | 101 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14051 R55684 |
Xiang - Labetalol, 2020 | Premature delivery (delivery before 37 weeks) | during pregnancy (anytime or not specified) | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication | 0.79 [0.46;1.37] C | 34/124 39/121 | 73 | 124 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14079 R55421 |
Gandjbakhch - Beta-blockers, 2018 | Preterm birth (<37 weeks of gestation) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 3.00 [0.17;51.75] C | 1/13 1/37 | 2 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13891 R54554 |
Ishibashi - Beta-blockers, 2017 | Premature birth (gestational period less than 37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 4.79 [1.51;15.21] | 10/38 6/87 | 16 | 38 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14071 R55397 |
Tanaka - Beta-blockers, 2016 | Preterm births | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 1.85 [0.81;4.21] C | 13/45 18/100 | 31 | 45 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13480 R51999 |
Orbach - Atenolol, 2013 | Preterm delivery (< 37 weeks of gestation) | 3rd trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 2.68 [1.57;4.56] | 18/107 7,836/97,820 | 7,854 | 107 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13448 R51807 |
Su - Beta-blockers (Controls unexposed, disease free), 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.69 [2.04;3.56] C excluded (control group) |
65/414 529/8,181 | 594 | 414 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13442 R51789 |
Su - Beta-blockers (Controls unexposed, sick) , 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 2.01 [1.42;2.86] | 65/414 84/1,006 | 149 | 414 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13882 R54320 |
Petersen - Beta-blockers, 2012 | Preterm birth (birth before the 37th gestational week) | 1st and 2nd trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 2.26 [2.03;2.52] | 697/2,459 109,163/909,226 | 109,860 | 2,459 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13392 R54162 |
Ray - Beta-blockers, 2001 | Preterm birth before 37 weeks gestation | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 4.00 [2.30;6.90] | 57/144 30/247 | 87 | 144 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13587 R52684 |
Lydakis - Atenolol, 1999 | Delivery <37 Weeks | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 2.75 [1.31;5.76] C | 26/78 14/91 | 40 | 78 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13976 R54826 |
Cruickshank - Labetalol, 1991 | Preterm delivery (< 37 weeks) | 3rd trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 0.94 [0.37;2.36] C | 10/51 13/63 | 23 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14027 R55127 |
Rosenfeld - Pindolol, 1986 | Preterm (<37wk) | during pregnancy (anytime or not specified) | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 1.20 [0.31;4.69] C | 6/23 5/22 | 11 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 17 studies | 1.78 [1.49;2.13] | 126,917 | 7,825 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = 0.5467 (by Egger's regression)
slope=0.6782 (0.0918); intercept=-0.4830 (0.7832); t=0.6167; p=0.5467
excluded 13448, 13509, 17151